查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1552571

前葡萄膜炎治療市場規模、佔有率、趨勢分析報告：按類型、治療、分銷管道、地區和細分市場預測，2024-2030 年

Anterior Uveitis Treatment Market Size, Share & Trends Analysis Report By Type (Infectious Uveitis), By Therapy (Biologics), By Distribution Channel (Hospital, Retail, Online Pharmacies), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

前葡萄膜炎治療市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球前葡萄膜炎治療市場規模將達到9.675億美元，2024年至2030年複合年成長率為12.6%。

這種疾病盛行率的上升預計將推動市場成長。與全葡萄膜炎、後葡萄膜炎和中間葡萄膜炎相比，這種疾病更常見。

根據《今日視網膜》 2017 年的一篇報導，這種疾病約佔葡萄膜炎病例的 30% 至 90%。它還指出，大約 1% 至 4% 的患者視力下降 25%。儘管該疾病有多種有效的治療方法並且易於管理，但很容易復發。這種疾病多見於青壯年族群。這在老年人中也很常見。眼部缺血和皰疹性葡萄膜炎是老年人群的常見原因。大多數病例發生在健康人群中，但有些病例與感染疾病、胃腸道疾病、風濕病、肺病和皮膚病有關。儘管這種疾病比後葡萄膜炎對視力的威脅較小，但在某些情況下可引起青光眼、白內障和黃斑囊黃斑部水腫。

前葡萄膜炎治療市場報告亮點

  • 2023 年的前葡萄膜炎治療市場將由皮質類固醇主導，因為它們具有減少眼部發炎的有益特性。皮質類固醇是主要的治療工具。
  • 由於抗 TNF 藥物生物製藥治療方法機會的擴大，預計抗 TNF 藥物在預測期內將表現出良好的成長率。
  • 由於免疫抑制劑擴大用於治療慢性前葡萄膜炎，因此在 2023 年佔據了重要的市場佔有率。
  • 2023 年的市場將由提供多種治療選擇的醫院藥屋主導
  • 由於折扣產品的便利性、易用性和可用性，預計線上藥局在預測期內將呈現顯著的複合年成長率。
  • 由於該地區的高盛行率和醫療保健支出，北美在 2023 年佔據了最大的銷售佔有率。
  • 由於該地區新興國家的感染疾病增加和可支配收入增加，預計亞太地區在預測期內將呈現良好的成長。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章前葡萄膜炎治療市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 前葡萄膜炎治療市場分析工具
    • 波特的分析
    • PESTEL分析

第4章前葡萄膜炎治療市場：按類型估計和趨勢分析

  • 細分儀表板
  • 前葡萄膜炎治療市場：2023 年和 2030 年按類型分類的變化分析
  • 傳染性葡萄膜炎
  • 非感染性葡萄膜炎

第5章前葡萄膜炎治療市場：依治療方法估計與趨勢分析

  • 細分儀表板
  • 前葡萄膜炎治療市場：2023 年和 2030 年治療的變異分析
  • 皮質類固醇
  • 免疫抑制治療
  • 生物製藥
  • 其他
  • 管道療法

第6章前葡萄膜炎治療市場：按分銷管道的估計和趨勢分析

  • 細分儀表板
  • 前葡萄膜炎治療市場：2023 年和 2030 年按分銷管道分類的變化分析
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章前葡萄膜炎治療市場：區域估計和趨勢分析

  • 2023 年和 2030 年前葡萄膜炎治療市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Novartis AG
    • Santen Pharmaceutical Co., Ltd
    • AbbVie Inc.
    • Kiora Pharmaceuticals, Inc.
    • Clearside Biomedical
    • Aldeyra Therapeutics, Inc.
    • UCB SA
    • Agilent Technologies, Inc.（Lux Biosciences, Inc.）
    • Tarsier Pharma Ltd.
簡介目錄
Product Code: GVR-3-68038-450-5

Anterior Uveitis Treatment Market Growth & Trends:

The global anterior uveitis treatment market size is expected to reach USD 967.5 million by 2030, registering a CAGR of 12.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of the disease is anticipated to aid market growth. This disease is more common when compared to panuveitis, posterior, and intermediate uveitis.

According to a 2017 article by Retina Today, this condition accounted for around 30% to 90% of the cases of uveitis. It also stated around 1% to 4% of patients experience 25% loss of visual acuity. There are different effective treatments for this disease and can be easily managed; however, it tends to recur. This disease is prevalent among both young and middle-aged group. It is also common among the geriatric population. Ocular ischemia and herpetic uveitis are the two most common causes of this disease among the geriatric population. Most of the cases occur in healthy people, however, some are associated with infectious diseases, gastrointestinal disorders, rheumatologic diseases, and lung & skin diseases. This disease is less sight-threatening as compared to posterior uveitis, however, in some cases might lead to glaucoma, cataract, and cystoid macular edema.

Anterior Uveitis Treatment Market Report Highlights:

  • Corticosteroids dominated the anterior uveitis treatment market in 2023 owing to its beneficial characteristic of minimizing inflammation in the eye. It is the primary treatment modality.
  • Anti-TNF agents are expected to exhibit lucrative growth rate over the forecast period due to growing opportunity in treatment methods with biologic therapy using Anti-TNF drugs.
  • Immunosuppressants held a significant market share in 2023 owing to their growing adoption for treatment of chronic anterior uveitis.
  • Hospital pharmacies dominated the market in 2023 due to the wide treatment options available there.
  • Online pharmacies are expected to witness significant CAGR over the forecast period due to convenience, ease, and availability of discounted products.
  • North America held the largest revenue share in 2023 owing to high prevalence as well as healthcare expenditure in this region.
  • Asia Pacific is anticipated to exhibit lucrative growth during the forecast period due to the rising number of infectious diseases in developing countries of the region and growing disposable income.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Anterior Uveitis Treatment Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Anterior Uveitis Treatment Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Anterior Uveitis Treatment Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Anterior Uveitis Treatment Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Infectious Uveitis
    • 4.3.1. Infectious Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Non-Infectious Uveitis
    • 4.4.1. Non-Infectious Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.1. Anterior Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.2. Pan-Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.3. Posterior Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.4. Intermediate Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Anterior Uveitis Treatment Market: Therapy Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Anterior Uveitis Treatment Market: Therapy Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Corticosteroids
    • 5.3.1. Corticosteroids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Immunosuppressive Therapies
    • 5.4.1. Immunosuppressive Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Biologics
    • 5.5.1. Biologics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Pipeline Therapies
    • 5.7.1. Pipeline Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Anterior Uveitis Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Anterior Uveitis Treatment Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Anterior Uveitis Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Anterior Uveitis Treatment Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. U K Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Anterior Uveitis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Novartis AG
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Santen Pharmaceutical Co., Ltd
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. AbbVie Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Kiora Pharmaceuticals, Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Clearside Biomedical
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Aldeyra Therapeutics, Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. UCB S.A.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Agilent Technologies, Inc. (Lux Biosciences, Inc.)
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Tarsier Pharma Ltd.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives